# OnCo record i-spy-2 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/i-spy-2/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "i-spy-2", "NCT01042379" ;
  schema:name "I-SPY 2"@en ;
  schema:alternateName "I-SPY 2 TRIAL"@en, "ISPY2"@en, "I-SPY2"@en ;
  schema:description "I-SPY 2 is a permanent, adaptive trial that tests new breast cancer drugs before surgery, steering each drug towards the tumour subtypes where it is working and graduating the winners in two years instead of ten. Several of its graduates became approved treatments."@en ;
  schema:url <https://onco.cc/trials/i-spy-2/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01042379>, <https://www.ispytrials.org/i-spy-platform/i-spy2>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1513749>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1513750>, <https://jamanetwork.com/journals/jamaoncology/fullarticle/2760405> ;
  onco:status "active" ;
  onco:phase "platform" ;
  schema:startDate "2010-03-01" ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/gene-expression-prognostic-assays/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/neratinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/trastuzumab-emtansine/>, <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/fianlimab/> ;
  onco:companies <https://onco.cc/companies/quantum-leap-healthcare-collaborative/> ;
  onco:institutions <https://onco.cc/institutions/ucsf/> ;
  onco:terms <https://onco.cc/terms/pcr/>, <https://onco.cc/terms/seamless-adaptive/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/master-protocol/> ;
  onco:people <https://onco.cc/people/laura-esserman/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-magbanua-ispy2-ctdna-neoadjuvant-ann-oncol-2021/>, <https://onco.cc/key-papers/paper-i-spy-2-jama-oncol-2020/> .